Thermo Fisher Scientific Earnings Preview: 12-Quarter Beat Streak on the Line
As seen on the 24/7 Wall St. homepage on October 21, 2026.
Twelve straight quarters of EPS beats go on the line at 6:00 AM ET, with consensus at $6.40 on $11.95 billion in revenue. The real tell is whether life-science tools and bioprocessing demand held up well enough to extend the run.
Continue ReadingShow less
Thermo Fisher Scientific reports before the open on October 21, 2026, putting one of the more consistent earnings records in the large-cap space to an immediate test. Twelve consecutive quarters of beating EPS estimates is the kind of streak that builds expectations fast, and those expectations are now baked into how the stock is priced.
Consensus heading into the report stands at $6.40 in earnings per share. That is the baseline the market has already accepted, so the margin of any beat is what moves the stock.
The segment that matters most is life-science tools and bioprocessing, where demand trends have been uneven across the industry after a post-pandemic inventory correction. If that demand held up well enough to drive upside, the streak survives, and even a narrow miss against $6.40 would carry real weight given how much the run has shaped sentiment.
Investors who follow this name closely will want to listen for any forward commentary on bioprocessing volumes and academic research funding, since those are the two variables most likely to shape the next quarter's setup.
Sources
Mentioned: TMO